Inventor · disambiguated record
David S. Jones
Also filed as: JONES DAVID · JONES DAVID S · JONES DAVID STANLEY
30 granted patents·18 pending applications·1,075 citations·filing 1987–2023
98Inventor score
Files withJOLLA PHARMA18NEORX CORP8VG INSTR GROUP3ALPHASONICS ULTRASONIC CLEANING SYSTEMS LTD2COUTTS STEPHEN M1
Top patents by PatentIndex Score
48 records- 0197US5552391AChemically-defined non-polymeric valency platform molecules and conjugates thereofJOLLA PHARMA·Filed 1993·Granted Sep 3, 1996·160 cites·12 claims
- 0293US5075099AMetal radionuclide chelating compounds for improved chelation kineticsNEORX CORP·Filed 1990·Granted Dec 24, 1991·121 cites·13 claims
- 0392US4988496AMetal radionuclide chelating compounds for improved chelation kineticsNEORX CORP·Filed 1988·Granted Jan 29, 1991·142 cites·13 claims
- 0490US7351855B2Chemically defined non-polymeric valency platform molecules and conjugates thereofJOLLA PHARMA·Filed 2003·Granted Apr 1, 2008·24 cites·143 claims
- 0590US4885153ARadiohalogenated for proteinsNEORX CORP·Filed 1989·Granted Dec 5, 1989·24 cites·24 claims
- 0689US6207160B1aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologiesJOLLA PHARMA·Filed 1996·Granted Mar 27, 2001·70 cites·25 claims
- 0789US5606047AChemically-defined non-polymeric valency platform molecules and conjugates thereofJOLLA PHARMA·Filed 1995·Granted Feb 25, 1997·65 cites·1 claims
- 0885US6060056AComposition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform moleculeJOLLA PHARMA·Filed 1993·Granted May 9, 2000·58 cites·56 claims
- 0984US6951939B2Multivalent platform molecules comprising high molecular weight polyethylene oxideJOLLA PHARMA·Filed 2001·Granted Oct 4, 2005·18 cites·170 claims
- 1083US5726329AModified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotidesJOLLA PHARMA·Filed 1995·Granted Mar 10, 1998·53 cites·11 claims
- 1180US5633395AChemically-defined non-polymeric valency platform molecules and conjugates thereofJOLLA PHARMA·Filed 1995·Granted May 27, 1997·33 cites·1 claims
- 1279US6458953B1Valency platform molecules comprising carbamate linkagesJOLLA PHARMA·Filed 1999·Granted Oct 1, 2002·16 cites·37 claims
- 1378US4794252ADischarge ionization mass spectrometerVG INSTR GROUP·Filed 1987·Granted Dec 27, 1988·22 cites·16 claims
- 1477US5391785AIntermediates for providing functional groups on the 5' end of oligonucleotidesJOLLA PHARMACEUTIAL COMPANY·Filed 1992·Granted Feb 21, 1995·32 cites·6 claims
- 1576US5874552AModified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotidesJOLLA PHARMA·Filed 1995·Granted Feb 23, 1999·29 cites·18 claims
- 1674US6858210B1Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using sameJOLLA PHARMA·Filed 1999·Granted Feb 22, 2005·33 cites·104 claims
- 1774US5786512AModified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotidesLAJOLLA PHARMACEUTICAL COMPANY·Filed 1994·Granted Jul 28, 1998·24 cites·2 claims
- 1873US6410775B1APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologiesJOLLA PHARMA·Filed 1998·Granted Jun 25, 2002·18 cites·5 claims
- 1972US4933470AMethod of synthesis of vicinal diaminesNEORX CORP·Filed 1987·Granted Jun 12, 1990·10 cites·12 claims
- 2071US5175257ARadiolabeled proteins for diagnostic or therapeutic useNEORX CORP·Filed 1991·Granted Dec 29, 1992·29 cites·36 claims
- 2170US7115581B2Chemically-defined non-polymeric valency platform molecules and conjugates thereofJOLLA PHARMA·Filed 2002·Granted Oct 3, 2006·1 cites·46 claims
- 2267US5112953ARadiolabeled proteins for diagnostic or therapeutic useNEORX CORP·Filed 1989·Granted May 12, 1992·30 cites·40 claims
- 2364US9993851B2Ultrasonic cleaning apparatus and methodALPHASONICS ULTRASONIC CLEANING SYSTEMS LTD·Filed 2014·Granted Jun 12, 2018·1 cites·12 claims
- 2464US2008293660A1Chemically-defined non-polymeric valency platform molecules and conjugates thereofJOLLA PHARMA·Filed 2008·Application pending·0 cites
- 2563US5625075AMetal radionuclide chelating compounds for improved chelation kineticsNEORX CORP·Filed 1995·Granted Apr 29, 1997·6 cites·4 claims
- 2662US6399578B1Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using sameJOLLA PHARMA·Filed 1999·Granted Jun 4, 2002·21 cites·22 claims
- 2760US2007254851A1Chemically-defined non-polymeric valency platform molecules and conjugates thereofCOUTTS STEPHEN M·Filed 2006·Application pending·0 cites
- 2859US2007191263A1Valency platform molecules comprising aminooxy groupsJOLLA PHARMA·Filed 2007·Application pending·0 cites
- 2958US5160841AIon source for a mass spectrometerKRATOS ANALYTICAL LTD·Filed 1991·Granted Nov 3, 1992·13 cites·13 claims
- 3058US2025226200A1Shield for ion source enclosureMICROMASS LTD·Filed 2023·Application pending·0 cites
- 3156US2002082400A1Conjugates of T cell epitope deficient immunogen analogs for humoral anergy and chemically defined non-polymeric valency platform moleculesFiled 2000·Application pending·0 cites
- 3256US2002107389A1Conjugates of chemically defined non-polymeric valency platform molecules and biologically active moleculesFiled 2000·Application pending·0 cites
- 3355US2004009904A1APL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologiesFiled 2002·Application pending·0 cites
- 3454US2005226844A1Valency platform molecules comprising carbamate linkagesJOLLA PHARMA·Filed 2005·Application pending·0 cites
- 3552US2001010818A1Methods and formulations for reducing circulating antibodiesFiled 2001·Application pending·0 cites
- 3652US2002160964A1Conjugates comprising galactose alpha 1,3 galactosyl epitopes and methods of using sameFiled 2002·Application pending·0 cites
- 3751US2005220785A1Methods and formulations for reducing circulating antibodiesENGLE STEVEN B·Filed 2005·Application pending·0 cites
- 3849US2005175620A1Multivalent platform molecules comprising high molecular weight polyethylene oxideJOLLA PHARMA·Filed 2005·Application pending·0 cites
- 3949US2005004351A1Therapeutic and diagnostic domain 1 beta2GP1 polypeptides and methods of using sameFiled 2004·Application pending·0 cites
- 4048US2005208480A1aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologiesVICTORIA EDWARD J·Filed 2004·Application pending·0 cites
- 4148US2003018190A1Valency platform molecules comprising carbamate linkagesFiled 2002·Application pending·0 cites
- 4247US4942296ASuper-critical fluid mass spectrometerVG INSTR GROUP·Filed 1988·Granted Jul 17, 1990·6 cites·15 claims
- 4347US2002155107A1Methods and formulations for reducing circulating antibodiesFiled 2002·Application pending·0 cites
- 4446US2006141597A1Valency platform molecules comprising aminooxy groupsJONES DAVID S·Filed 2005·Application pending·0 cites
- 4545US2004224366A1Valency platform molecules comprising aminooxy groupsFiled 2004·Application pending·0 cites
- 4642US4891515ASolution analyzing mass spectrometerVG INSTR GROUP·Filed 1988·Granted Jan 2, 1990·12 cites·10 claims
- 4738US5436352AMetal radionuclide chelating compounds for improved chelation kineticsNEORX CORP·Filed 1991·Granted Jul 25, 1995·4 cites·5 claims
- 4830US10350650B2Relating to ultrasonic cleaningALPHASONICS ULTRASONIC CLEANING SYSTEMS LTD·Filed 2013·Granted Jul 16, 2019·0 cites·9 claims
Join the waitlist — get patent alerts
Get an alert when David S. Jones files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →